DEA Blocks Medical Marijuana Patient From Rescheduling Hearing

DEA Denies Patient Testimony Request

The Drug Enforcement Administration rejected a petition from a medical marijuana patient who sought to provide direct testimony at the Schedule III rescheduling hearing. The denial, published July 11 in the Federal Register, stated that the petitioner didn't meet the agency's criteria for standing as a party to the administrative law proceeding. The DEA's notice didn't name the individual but confirmed the petition was filed by a self-identified medical cannabis patient seeking to speak to therapeutic benefits.

The agency's Administrative Law Judge hearing is scheduled for December 2026. The DEA has approved testimony from pharmaceutical companies, cannabis research organizations, and advocacy groups including the Coalition for Cannabis Scheduling Reform and the Cannabis Industry Association. No individual patients have been granted standing.

Standing Requirements Exclude Patient Voices

The DEA requires petitioners to demonstrate a direct legal or economic interest in the rescheduling outcome to qualify for witness status. Medical marijuana patients using state-legal programs don't meet that threshold under current agency interpretation, according to administrative law experts. The standard was established in prior DEA scheduling proceedings. It hasn't been modified for the cannabis rescheduling process.

Here's what the denial means: the DEA views rescheduling as a regulatory matter between federal agencies and commercial stakeholders, not a patient-rights issue. That framing has drawn criticism from medical cannabis advocates who argue that patient experience constitutes material evidence of therapeutic value under the Controlled Substances Act's five-factor test.

December Hearing to Focus on Scientific Evidence

The December administrative hearing will center on the Health and Human Services recommendation to move cannabis from Schedule I to Schedule III. Approved witnesses include representatives from the American Medical Association, the National Institute on Drug Abuse, and multiple cannabis testing laboratories. DEA Administrative Law Judge John Mulrooney will conduct the hearing, which is expected to last five days.

HHS delivered its recommendation to the DEA in August 2023, citing accepted medical use and lower abuse potential relative to Schedule I and II substances. The DEA opened the formal rulemaking process in May 2024 with a Notice of Proposed Rulemaking published in the Federal Register. The December hearing represents the final evidentiary phase before the agency issues a final rule.

Advocacy Groups Push for Patient Inclusion

Medical marijuana advocacy organizations have called the exclusion of patient testimony a procedural failure that undermines the scientific record. Americans for Safe Access and the Multidisciplinary Association for Psychedelic Studies both submitted comments to the DEA in June urging the agency to broaden standing criteria. Neither organization has been granted direct witness status, but both are listed as interested parties eligible to submit written comments.

As of July 10, the DEA has accepted more than 43,000 public comments on the proposed rule. The comment period closed June 30. The agency isn't required to respond individually to comments but must address substantive themes in the final rule preamble.

What Happens After the Hearing

The DEA will issue a final rule on cannabis scheduling within 90 days of the December hearing's conclusion, according to the agency's projected timeline. That rule can affirm the Schedule III recommendation, reject it and maintain Schedule I status, or propose an alternative classification. Federal courts can review the final rule, and multiple industry groups have indicated they'll challenge any outcome that doesn't remove cannabis from the Controlled Substances Act entirely.

Publication of the final witness list is expected by August 15. That's the next procedural milestone. Approved witnesses will receive detailed instructions on testimony format, time limits, and cross-examination protocols. The hearing will be open to the public but won't accept live public comment.